Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline Asciminib Combination in Chronic Phase CML
NCT03906292Phase 2Active, not recruiting
- Sponsor
- Friedrich Schiller University Jena
- Start
- Aug 2019
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of asciminib in chronic myeloid leukemia (CML) (5 arms), sponsored by Friedrich Schiller University Jena. Primary endpoints: Deep Molecular Response (Rate of MR4) at 12 months and Deep Molecular Response (Rate of MR4.5) at 36 months. Started Aug 2019; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03906292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906292.